Enzymlogic was announced the winner of the Most Innovative Startup Award and one of the three finalist in the Life Science category at the prestigious Entrepreneur XXI Awards ceremony.
The ceremony marks the culmination of a year-long decision-making process which began with over 545 applications and ended with just 15 finalists attending the event in the hope of becoming one of the winners. An extensive and prestigious judging panel has been involved in the robust awards process, which included written submissions and face-to-face presentations. Entrants have been judged on a vast array of business markers, including technological innovation, growth potential and global vision.
The Entrepreneur XXI Awards, considered as one of the reference calls for innovation projects in Spain, are organized by “la Caixa”, through Caixa Capital Risc, together with the Ministry of Industry, Energy and Tourism, through Enisa (National Innovation Company). The awards have distinguished the best companies in the categories of Life Sciences, Information Technology, Digital Business, Agrifood and Industrial Technologies, Social Entrepreneurship and Technological Innovation.
Upon receiving the award, Enzymlogic founders Ana Corrionero and Patricia Alfonso emphasized: “Being named the Most Innovative Startup is a great honor for a contract research organization like Enzymlogic. This is our second award for innovation this year, once again validating our vision, cutting-edge technology and the hard work we have put in to exceeding our customers’ expectations by enabling the discovery of inhibitors with novel modes of binding and powering high-performance Binding Kinetics campaigns. We are also delighted that the Entrepreneur XXI Awards’ impressive panel of experts has recognized as one of the three finalist in the Life Science category.”
The winners of each sector have obtained a cash prize of €25,000 and a personalized mentoring program valued at 25,000 euros, with activities adapted to the needs and stage of development, and preferential access to the financing of Caixa Capital Risc and Enisa. The three finalists of each sector will also accede gratuitously to the mentoring program. Additionally, the winner of the Most Innovative Startup Award, supported by the Embassy of Israel in Spain, will take part in an intense, five-day startup experience in Tel Aviv’s startup ecosystem.
Enzymlogic offers in vitro biochemical and cell-based assays to the biotechnological and pharmaceutical companies, life science laboratories and academic groups. Our binding kinetics, kinetic selectivity, assay development, profiling and screening services enable faster and cost-effective drug discovery by identifying the most promising drug candidates as well as withdrawing those compounds likely to fail in pre-clinical development. Additionally, Enzymlogic’s pioneering approach provides predictive tools that deliver physiologically relevant insights earlier in the drug discovery process.
About Caixa Capital Risc
Caixa Capital Risc, the venture capital arm of La Caixa, is an investor that provides equity and convertible loans to innovative companies in their early stages.
This is a public-owned company attached to the Ministry of Industry, Energy and Tourism through the Directorate General of Industry and SME, whose activity is chiefly focused on searching out and using new financial support instruments for SMEs.